Caspase-1, IL-1β, and IL-18 are down-regulated in NSCLC tumor tissues, and simvastatin activates NLRP3-caspase-1-IL-1β and IL-18 pathways to induce pyroptosis and inhibit NSCLC cell migration. Here, IL1B is linked to neoplasm.